This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bristol-Myers Reports Data from Opdivo Combination Studies
by Zacks Equity Research
Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda
by Arpita Dutt
This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.
Heat Biologics Stock Falls on Negative Bladder Cancer Data
by Zacks Equity Research
Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.
ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.
The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
Stock Market News for August 10, 2016
by Zacks Equity Research
Benchmarks closed narrowly in the green as drop in oil prices and disappointing productivity data offset some of the gains in healthcare and consumer staples stocks
Stock Market News for August 09, 2016
by Zacks Equity Research
Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks
BLS Reports Robust July Jobs: 255K, 4.9% Unemployment
by Mark Vickery
Also, May's paltry 11K jobs was more than doubled to 24K, and even June's strong 287K rose another 5000 jobs to 292K.
Bull of the Day: Bristol-Myers Squibb (BMY)
by Neena Mishra
This specialty pharma giant is a leader in innovative cancer treatments.
Don't Make It Complicated, Own Drug Stocks
by John Blank
The basic ingredients for rising drug demand -- the frailties that accompany aging -- are going to be there for the next 2 decades, in the USA and elsewhere.